Pentadeca Arginate (PDA): Evidence, Mechanism & Legal Status

Pentadeca Arginate — marketed as PDA, pentadecapeptide arginate, BPC-157 arginate, or "BPC-157 stable" — is the L-arginine (di-arginine) salt of BPC-157, promoted for tendon, ligament and muscle repair, gut and mucosal healing, and wound recovery.5 Its popularity in recovery circles has surged since 2024; its proof in humans is nonexistent. This monograph separates the rebrand from the reality.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. PDA is not an FDA-approved drug; it is sold as a "research chemical not for human use" and is prohibited in sport. Dosing figures are reported strictly as seen in clinic and marketing materials for completeness — not as recommendations. Consult a licensed clinician before any health decision.

What is Pentadeca Arginate and how does it work?

"Penta-deca" means fifteen amino acids; "arginate" names the arginine counter-ion. PDA is therefore BPC-157 by another name — the same sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV), free-peptide molecular weight about 1419.55 Da, differing only in the salt paired with the peptide backbone.43 The arginate form was defined in a 2013 Diagen patent (WO2014142764A1, inventor Rudolf Ručman) as the "bepecin di-L-arginine salt" at a 1:2 molar ratio of peptide to L-arginine, pH-adjusted to 7.40.3

The mechanism story is entirely the parent peptide's, demonstrated only in animal and in-vitro models because the active molecule is identical. Reported signaling includes pro-angiogenic activation of VEGF receptor-2 (VEGFR2) and the early growth response gene EGR-1; modulation of the nitric-oxide system via eNOS-derived NO and cGMP/PKG; and induction of antioxidant proteins such as HO-1 and NQO-1.4 A 2025 systematic review summarizes the musculoskeletal mechanism as enhanced growth-hormone-receptor expression plus angiogenesis with reduced inflammatory cytokines.1 No single primary receptor target is confirmed, and none of this is established in humans. There are no published human pharmacokinetic data for PDA or BPC-157 in any salt form; the only PK work (rats and beagle dogs) reports an elimination half-life under about 30 minutes, with hepatic metabolism and renal and biliary excretion.4

What is the one thing the arginine salt genuinely changes?

Exactly one PDA-specific claim has primary data behind it: chemical and storage stability. The Diagen patent provides HPLC measurements under several stressors, all showing the di-arginine salt dramatically outperforming the acetate.3

This is a real storage-stability and gastric-survival advantage rooted in chemistry: the arginine guanidinium group buffers toward neutral pH and suppresses acid-catalyzed degradation of the peptide's aspartate and glutamate residues.3 But two caveats are decisive. First, popular vendor figures such as "1,000 times more stable" and oral bioavailability rising "from under 3 percent to over 90 percent" are marketing extrapolations from these chemistry numbers, not pharmacokinetic measurements, and appear in no peer-reviewed study.5 Second, for the subcutaneous or intramuscular route most clinics actually use, the gastric-stability edge is largely irrelevant because the peptide bypasses the stomach. Once dissolved in tissue, the free BPC-157 peptide is delivered and its in-vivo pharmacology is expected to match the acetate.5

What is the evidence by indication?

The central finding of this monograph is an absence: no PDA-specific studies exist. The 2025 PRISMA systematic review of the parent compound screened 544 articles from 1993 to 2024 and included 36 — of which 35 were preclinical and only one was human.1 Not one studied PDA. Every indication below is therefore borrowed BPC-157 evidence, graded C at best and D as "PDA."

The orthopedic case is the most extrapolated. Rodent models report improved healing of tendon, ligament, muscle and bony injuries, plausibly via angiogenesis and fibroblast outgrowth.1 The single human datapoint across the entire field is an uncontrolled, unblinded retrospective case series of 12 chronic-knee-pain patients given intra-articular BPC-157, in which 7 of 12 reported relief beyond six months — no control, no blinding, no validated outcomes, and not the arginate salt.1 The gut indication is where the arginate's stability edge is invoked as a rationale for oral PDA, but that rationale is theoretical, not demonstrated in any human or PDA-specific study.3 Readers can confirm the evidence gap directly via the negative PubMed query at pubmed.ncbi.nlm.nih.gov.2

What doses appear in the literature?

Reported strictly as information, not a protocol — and clinics themselves concede no officially established human dosage exists for PDA.6 The most common route is subcutaneous injection, often near the injury site, with intramuscular also used and oral capsule forms marketed on the arginate's acid stability.6 Reported SC/IM figures are commonly cited around 200 to 250 µg per day starting, up to roughly 300 to 500 µg per day for more significant injury; some clinic protocols describe a loading phase of 500 µg to 1 mg per day for 7 to 10 days followed by 500 µg to 1 mg two to three times weekly — all mirroring conventional BPC-157 anecdotal dosing, with no validated titration or duration.6 Lyophilized powder is reconstituted with bacteriostatic water per vendor instructions.3 Because PDA is sold gray-market as "research use only," product identity, purity, dose accuracy and sterility are unverified.8

How safe is Pentadeca Arginate?

No clinical safety dataset exists; the systematic review found no clinical safety data for BPC-157.1 Anecdotal reports describe mild injection-site irritation, headache, nausea and dizziness, and the literature documents that the peptide has caused pain and possible necrosis when injected in aqueous or physiological-saline solution.4 Animal toxicology is reassuring at studied doses — no deaths or abnormal findings at 20 mg/kg i.m. in rats or 10 mg/kg i.m. in dogs — but human exposure is far too sparse to detect anything beyond obvious reactions.4 The dominant theoretical risk is mechanistic: PDA upregulates VEGFR2 and stimulates EGR-1, and because VEGF-family signaling is expressed in roughly half of studied human cancers, reviewers warn the peptide "may not be the right choice" where occult cancer cells could be present.4 Pregnancy, breastfeeding and pediatric use are precautionary contraindications. In practice the largest real-world hazard is product quality from gray-market vendors — unverified identity, endotoxin and heavy-metal content.8

What is the FDA and WADA status in 2026?

PDA is not an FDA-approved drug, has no USP/NF monograph, and is not a component of any approved drug, so it meets none of the three statutory criteria for legal 503A bulk compounding.8 Critically, "pentadeca arginate" is not separately listed on any FDA bulks list — nominations address only BPC-157 free base and acetate — confirming PDA tracks BPC-157's fate rather than escaping it.9 PDA emerged after the late-2023 Category 2 classification of BPC-157, with vendors arguing the arginine counter-ion made it a distinct entity, but under the FDA's "essentially a copy" doctrine a salt change with the same active sequence and route is not a legally distinct substance.810 On April 15, 2026 the FDA removed 12 peptides — including BPC-157 — from 503A Category 2, but only because the nominations were withdrawn, not because the substances were found safe; this leaves BPC-157 and PDA in an unauthorized transitional gray zone.11 A Pharmacy Compounding Advisory Committee review is scheduled for July 23-24, 2026 (docket FDA-2025-N-6895), but PCAC votes are advisory only and the earliest plausible legal compounding access is late Q3 2026, with nothing guaranteed.912

For athletes the picture is unambiguous. BPC-157 in any salt form, including PDA, is prohibited at all times under category S0 (non-approved substances) of the WADA Prohibited List — in and out of competition, with no Therapeutic Use Exemption, and the salt form does not alter the classification.7 The U.S. Department of Defense also prohibits it for service members. "Research use only" labeling is not a shield: selling "not for human consumption" while supplying dosing and healing testimonials renders the research label legally void.8

Bottom line. Pentadeca Arginate is a marketing rebrand, not a new drug — the arginine salt of BPC-157, premised on a salt-form "distinctness" no regulator, monograph or court has accepted. The evidence gap is the verdict: zero PDA-specific studies of any kind, and a borrowed BPC-157 base that is 35-to-1 preclinical-to-human with no completed RCTs. Graded D as "Pentadeca Arginate," C only if generously crediting the parent preclinical base — legally unsettled and banned in sport. Regulatory facts here are current as of June 2026; the July 23-24, 2026 PCAC outcome was pending at the time of writing and should be re-verified after that date.